Afficher la notice abrégée

Epstein-Barr virus biomarkers have no prognostic value in HIV-related Hodgkin lymphoma in the modern combined antiretroviral therapy era

dc.rights.licenseopenen_US
dc.contributor.authorLUPO, J.
dc.contributor.authorGERMI, R.
dc.contributor.authorLANCAR, R.
dc.contributor.authorALGARTE-GENIN, M.
dc.contributor.authorHENDEL-CHAVEZ, H.
dc.contributor.authorTAOUFIK, Y.
dc.contributor.authorMOUNIER, N.
dc.contributor.authorPARTISANI, M.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBONNET, Fabrice
dc.contributor.authorMEYOHAS, M. C.
dc.contributor.authorMARCHOU, B.
dc.contributor.authorSEMANOVA, T.
dc.contributor.authorPREVOT, S.
dc.contributor.authorCOSTAGLIOLA, D.
dc.contributor.authorMORAND, P.
dc.contributor.authorBESSON, C.
dc.date.accessioned2020-06-29T07:05:54Z
dc.date.available2020-06-29T07:05:54Z
dc.date.issued2019-05-01
dc.identifier.issn0269-9370en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/8249
dc.description.abstractEnOBJECTIVES: Epstein-Barr virus (EBV) has been implicated in lymphomagenesis of HIV-related classical Hodgkin lymphoma (HIV-cHL). The utility of EBV molecular and serological biomarkers has scarcely been examined in HIV-cHL in the recent combined antiretroviral therapy (cART) era. DESIGN: We evaluated EBV DNA load and a panel of EBV antibodies in HIV-cHL patients prospectively enrolled in the French ANRS-CO16 Lymphovir cohort between 2008 and 2015. METHODS: Pretreatment whole blood, plasma EBV DNA load and serological profiles were analysed in 63 HIV-infected patients diagnosed with cHL. For the 42 patients with available material, comparisons were performed between values at diagnosis and 6 months after the initiation of chemotherapy. RESULTS: Pretreatment whole blood and plasma EBV DNA loads were positive in 84 and 59% of HIV-cHL patients, respectively. Two-year progression-free survival estimates did not differ between the patients with pretreatment whole blood (n = 53) or plasma (n = 37) EBV DNA(+) and the patients with pretreatment whole blood (n = 10) or plasma (n = 26) EBV DNA(-) (92 vs. 80% or 89 vs. 92%, P = 0.36 and 0.47, respectively). At diagnosis, 47% of patients harboured an EBV reactivation serological profile. Following chemotherapy, whole blood and plasma EBV DNA levels significantly declined from medians of 1570 [interquartile range, 230-3760) and 73 (0-320) copies/ml to 690 (0-1830) and 0 (0-0) copies/ml, respectively (P = 0.02 and P < 0.0001, respectively]. Anti-EBV IgG antibody level significantly dropped at 6-month follow-up (P = 0.004). CONCLUSION: Whole blood and plasma EBV DNA loads do not constitute prognostic markers in HIV-cHL patients in the modern cART era.
dc.language.isoENen_US
dc.subject.enMORPH3Eus
dc.title.enEpstein-Barr virus biomarkers have no prognostic value in HIV-related Hodgkin lymphoma in the modern combined antiretroviral therapy era
dc.title.alternativeAidsen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1097/qad.0000000000002129en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed30946153en_US
bordeaux.journalAIDS (London, England)en_US
bordeaux.page993-1000en_US
bordeaux.volume33en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue6en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=AIDS%20(London,%20England)&amp;rft.date=2019-05-01&amp;rft.volume=33&amp;rft.issue=6&amp;rft.spage=993-1000&amp;rft.epage=993-1000&amp;rft.eissn=0269-9370&amp;rft.issn=0269-9370&amp;rft.au=LUPO,%20J.&amp;GERMI,%20R.&amp;LANCAR,%20R.&amp;ALGARTE-GENIN,%20M.&amp;HENDEL-CHAVEZ,%20H.&amp;rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée